Overview

A PK and Safety Study in Subjects With Hepatic Impairment

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Assess the single dose PK and safety of TR701 FA in subjects with Moderate or Severe hepatic impairment versus matched control subjects with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Trius Therapeutics LLC
Treatments:
Tedizolid phosphate
Torezolid phosphate